Advanced Filters
noise

Lymphocytic Leukemia, Acute Clinical Trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 495 clinical trials
V Vanessa Fabrizio, MD

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.

3 - 30 years of age All Phase 1
F Francesca del Bufalo, MD

Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL

This is a phase I, open label study to evaluate the safety, identify the recommended dose (RD) and obtain preliminar evidence of the efficacy of allogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells in pediatric and young adults patients with relapsed/refractory B-cell precursor Acute Lymphoblastic Leukemia (BCP-ALL).

1 - 35 years of age All Phase 1

Efficacy, Safety and Limitations of Spinal Block for All Infants Under 3 Months

Spinal anesthesia (SA) has been shown to be a viable alternative to general anesthesia (GA) for infants and children for a variety of surgical procedures. SA serves to avoid some of the potential risks of GA including the need for airway manipulation, hemodynamic instability, postoperative apnea, and exposure to medications …

1 - 3 years of age All Phase N/A

Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access

This non-blinded, non-randomized pre-post study will examine the impact of providing CGM sensors free of charge to adult patients of Fair Haven Community Health Care with poorly controlled type 2 diabetes on glycemic control and quality of life.

18 years of age All Phase N/A
R Rehab A Soliman, Lecturer

Evaluation of Bone Changes Around Implants in Patients Treated With All on Four

The Goal of the clinical trail is to evaluate the Bone height changes around two axially placed anterior implants and two distally inclined 30-degree angle posterior implants in comparison to two axially placed anterior implants and two distally inclined 45-degree angle posterior implants using cone beam CT (CBCT). Patients will …

50 - 65 years of age All Phase N/A

GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.

18 - 45 years of age All Phase 1/2
P Penn Brain Tumor Center Research

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

This is a Phase II study of the combination of All-Trans Retinonic Acid (ATRA) and PD-1 inhibition (Retifanlimab) in patient with recurrent IDH-mutant glioma. The Sponsor-Investigator hypothesizes that the proposed regimen will be safe and stimulate a robust anti-tumor immune response.

18 years of age All Phase 2
X Xiao-Fan Zhu, M.D.

CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL

This is a phase II clinical study to evaluate the safety and efficacy of CAR-T-19 injection in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

- 25 years of age All Phase 2
J Jin Jie

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

ETP-ALL is a subtype of T-cell acute lymphoblastic leukemia (T-ALL) with poor outcomes and prognosis. Effective induction therapy is crucial in improving the treatment effect. Based on our laboratory research and clinical practice, the venetoclax plus HAG regimen shows promising efficacy in treating ETP-ALL. Therefore, we plan to conduct a …

14 - 75 years of age All Phase 3
X Xiaoming Liu, MD

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

3 - 18 years of age All Phase 1/2

Simplify language using AI